Taguchi I, Hara I, Gohji K, Arakawa S, Kamidono S
Department of Urology, Kobe University, School of Medicine, Chuo-ku, Kobe 650, Japan.
Int J Oncol. 1998 Jul;13(1):145-9. doi: 10.3892/ijo.13.1.145.
The synergistic anti-tumor effect of 13-cis retinoic acid (13-cRA) and interferon-alpha/beta (IFN-alpha/beta) was investigated using a highly metastatic mouse renal cell carcinoma cell subline (RenCa/F). Although 13-cRA inhibited tumor growth in vivo as well as in vitro, IFN-alpha/beta did not. Combined administration of 13-cRA and IFN-alpha/beta significantly enhanced the anti-tumor effect of 13-cRA. The retinoic acid receptor (RAR)-alpha and RAR-gamma were expressed in RenCa/F cells. Treatment with IFN-alpha/beta did not influence the expression level of these receptors at the mRNA level, which suggests that the synergism of 13-cRA and IFN-alpha/beta is not mediated through the RAR.
使用高转移性小鼠肾细胞癌细胞亚系(RenCa/F)研究了13-顺式维甲酸(13-cRA)与α/β干扰素(IFN-α/β)的协同抗肿瘤作用。尽管13-cRA在体内和体外均抑制肿瘤生长,但IFN-α/β却没有。13-cRA与IFN-α/β联合给药显著增强了13-cRA的抗肿瘤作用。维甲酸受体(RAR)-α和RAR-γ在RenCa/F细胞中表达。用IFN-α/β处理在mRNA水平上不影响这些受体的表达水平,这表明13-cRA与IFN-α/β的协同作用不是通过RAR介导的。